SUBSCRIBE
SUBSCRIBE

Elicio Therapeutics

IN THE PRESS
Press Releases
Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial
December 12, 2025
 · 
10 min read
Press Releases
Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer
November 20, 2025
 · 
7 min read
Press Releases
Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
November 14, 2025
 · 
12 min read
Press Releases
Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC
November 10, 2025
 · 
13 min read
Press Releases
Elicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting
November 4, 2025
 · 
8 min read
Press Releases
Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial
October 28, 2025
 · 
9 min read
Press Releases
Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma
September 30, 2025
 · 
9 min read
Press Releases
Elicio Therapeutics Reports Inducement Grants - September 18, 2025
September 18, 2025
 · 
2 min read
Press Releases
Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial
September 18, 2025
 · 
11 min read
Press Releases
Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients
August 13, 2025
 · 
11 min read
Load More
JOBS